Clinical Trials Browser

Phase 2 × Unknown × Immune Checkpoint Inhibitors × Clear all

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT05520814 2023-09-21

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Phase 2 Unknown

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT06047860 2023-09-21

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Phase 2 Unknown

Neoplasms

NCT05994456 2023-08-16

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT05871684 2023-08-01

A Combination Study of CAR-T Therapy in r/r B-NHL

Phase 2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT05845268 2023-05-06

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Phase 2 Unknown

Gastrointestinal

Locally Advanced Rectal Cancer

NCT05790447 2023-03-30

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Phase 2 Unknown

Neoplasms

NCT05048017 2023-03-29

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05218629 2023-03-29

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Phase 2 Unknown

Overall Survival

NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Phase 2 Unknown

Carcinoma, Transitional Cell

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05163483 2023-03-06

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05193188 2023-02-16

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Phase 2 Unknown

Chondrosarcoma

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Phase 2 Unknown

Adenocarcinoma of Lung

NCT05603013 2022-11-02

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Phase 2 Unknown

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05509478 2022-09-10

LEADER-001

Phase 2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT05530200 2022-09-07

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Phase 2 Unknown

Neoplasm Metastasis

NCT05520853 2022-08-30

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

Phase 2 Unknown

Hyperthermia, Carcinoma, Non-Small-Cell Lung

NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Phase 2 Unknown

Other solid neoplasm

Advanced Refractory Solid Tumors

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Phase 2 Unknown

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05371197 2022-05-12

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT05007145 2021-12-21

REVO

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05137886 2021-12-17

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase 2 Unknown

Hodgkin Disease, Recurrence

NCT04814043 2021-09-22

PLATIC

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05035381 2021-09-05

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

Phase 2 Unknown

GastrointestinalOther solid neoplasm

MSI-H Advanced Colorectal Cancer

NCT04539444 2021-08-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Phase 2 Unknown

Lymphoma, Non-Hodgkin, Recurrence

NCT04941417 2021-06-28

Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04922450 2021-06-10

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04814030 2021-04-23

AIPD-1

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT04769076 2021-02-25

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT04613804 2020-11-03

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04606108 2020-10-28

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Phase 2 Unknown

Sarcoma

NCT03987698 2020-07-07

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Phase 2 Unknown

Carcinoma, Renal Cell

NCT04353479 2020-04-20

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04294511 2020-03-04

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma

Phase 2 Unknown

Osteosarcoma

NCT04239443 2020-01-27

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Phase 2 Unknown

GynecologicSarcoma

Sarcoma, Uterine Neoplasms

NCT03994744 2019-08-28

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

Phase 2 Unknown

Small Cell Lung Carcinoma